

CONFIDENTIAL



**NOTIFICATION PURSUANT TO**

**18 V.S.A. § 4637(c)**

**Subject:** Notification Pursuant to 18 V.S.A. § 4637(c)

To the Office of the Attorney General of Vermont:

On August 23, 2019, Genentech USA, Inc. ("Genentech") notified the Office of the Attorney General of Vermont of a new prescription drug (Rozlytrek 200mg 90 capsules), pursuant to § 4637(b). Genentech hereby notifies the Attorney General of Vermont of the following additional information, pursuant to § 4637(c):

<b>Name of New Prescription Drug</b>	<b>NDC Number</b>	<b>Date of Commercial Availability</b>	<b>WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)</b>
Rozlytrek 200mg 90 capsules	50242-0094-90	August 21, 2019	\$16,800.00

**Description of the marketing and pricing plans used in the launch of Rozlytrek 200mg 90 capsules in the United States and internationally:**

Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.

We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn't prevent our medicines getting to people who need them.

**Rozlytrek 200mg 90 capsules received FDA approval for breakthrough therapy designation and priority review.**

**The estimated volume of patients who may be prescribed Rozlytrek 200mg 90 capsules:**

Genentech does not publicly disclose the estimated volume of patients who may be prescribed Rozlytrek 200mg 90 capsules.

**The date and price of acquisition if the drug was not developed by the manufacturer:**

Rozlytrek 200mg 90 capsules was not acquired from a third party.

Sincerely,

Maria Aquilina  
Director, Government Programs  
Genentech USA, Inc.